Longgang 姜

Dr. Longgang 姜


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2025 in Brazilian Journal of Otorhinolaryngology
Verified
Journal Article
Open access
HCHan Chen
Han Chen
LWLin Wang
Lin Wang
JZJisheng Zhang
Jisheng Zhang
XYXudong Yan
Xudong Yan
L姜Longgang 姜
Longgang 姜
YJYan Jiang
Yan Jiang
Direct comparison of the long-term effectiveness and safety of biologics for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is lacking. The study aimed to compare the long-term efficacy and safety of various biologics in the management of CRSwNP. The PubMed, Embase, Cochrane Library, and Web of Science databases were searched from database inception to March 2024, to identify all relevant literature on the use of biologics for CRSwNP. The research protocol was registered on PROSPERO.Two independent reviewers screened the studies, extracted the data, and performed a quality assessment using the Cochrane Risk of Bias tool. Network meta-analysis was conducted using STATA 17.0 and Review Manager (Version 5.3). Six studies with a minimum follow-up period of 52-weeks were analyzed, demonstrating the superior long-term efficacy of dupilumab compared to the other three biologics. The surface under the cumulative ranking curve were 100% for Nasal Polyp Score (NPS), 72.7% for Sino-Nasal Outcome Test-22 (SNOT-22), 94.6% for Visual Analogue Scale (VAS), and 100% for Nasal Congestion Score (NCS). In the comparison of NPS, dupilumab showed improvements of 1.84 (95% Confidence Interval [95% CI 0.78, 2.91]) over mepolizumab and 2.31 (95% CI 0.99, 3.63) over benralizumab. Among the symptom scores evaluated, only dupilumab achieved a significant improvement in NCS compared to benralizumab, with an improvement of 0.74 (95% CI 0.86, 1.19). No significant differences in adverse events was observed between biologics treatment or versus placebo. Treatment with dupilumab in patients with CRSwNP has shown superior long-term efficacy in reducing NPS and various symptom scores compared to other biologics. However, the results should be interpreted with caution due to the heterogeneity of patient characteristics across the included studies (e.g., disease severity, history of surgery, use of oral corticosteroids).

8 November 2023 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
SLShunke Li
Shunke Li
ZZZengxiao Zhang
Zengxiao Zhang
LWLin Wang
Lin Wang
XYXudong Yan
Xudong Yan
YJYan Jiang
Yan Jiang
L姜Longgang 姜
Longgang 姜

28 March 2024 in The Laryngoscope
Verified
Journal Article
Closed access
JZJiajia Zi
Jiajia Zi
ZWZhaoxia Wei
Zhaoxia Wei
LWLin Wang
Lin Wang
XYXudong Yan
Xudong Yan
SZShengnan Zhang
Shengnan Zhang
YJYan Jiang
Yan Jiang

29 November 2024 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
HCHan Chen
Han Chen
LWLin Wang
Lin Wang
JZJisheng Zhang
Jisheng Zhang
XYXudong Yan
Xudong Yan
L姜Longgang 姜
Longgang 姜
YJYan Jiang
Yan Jiang

4 September 2023 in World Journal of Otorhinolaryngology - Head and Neck Surgery
Verified
Journal Article
Open access
CZChunge Zheng
Chunge Zheng
L姜Longgang 姜
Longgang 姜
YJYan Jiang
Yan Jiang
Objectives: Radiation‐induced rhinosinusitis is a vital dose‐limiting reaction in patients with head and neck malignancy. Unlike oral mucositis during or after radiotherapy, radiation‐induced sinusitis is easily overlooked in clinical practice and rarely included in experimental studies. Herein, we review the literature to date on radiation‐induced rhinosinusitis.Methods: Relevant studies published between 1995 and 2022 were determined through a detailed search using open keywords from PubMed, with manual search of the reference list of the identified articles. Keywords searched were “ionizing radiation,” “radiotherapy,” “intensity‐modulated radiotherapy,” “head and neck tumor,” “nasopharyngeal carcinoma,” “nasal epithelium,” “radiation damage,” and “radiation‐induced rhinosinusitis.” Full‐text articles that clearly stated the pathogenesis, clinical manifestation, predictors, treatment, and prognosis of radiation‐induced rhinosinusitis were included.Results: Radiation‐induced rhinosinusitis occurs during radiotherapy and can last for months or even years after radiotherapy. A mixture of cellular outcomes caused by ionizing radiation and persistent damage of the epithelial and submucosal tissues after the treatment result from the radiotherapy itself. Endoscopic sinus surgery improves symptoms but can be accompanied by intraoperative and postoperative complications. Nasal irrigation, steroids, and antibiotics appear to reduce inflammation and relieve symptoms to a certain extent. Studies on other potentially useful drugs are underway and in the exploration stage, without clinical application.Conclusions: Despite its high incidence, radiation‐induced rhinosinusitis is a type of dose‐limiting toxicity that theoretically does not produce fatal effects at controlled doses and with adequate follow‐up care. In moderate‐to‐severe cases, toxicity may be present. Currently, radiation‐induced rhinosinusitis has potential prevention and treatment strategies. However, no unified management protocol has shown significant improvement in radiation‐induced rhinosinusitis. Further research is necessary.

23 February 2024 in International Archives of Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
DLDanyang Li
Danyang Li
JZJisheng Zhang
Jisheng Zhang
LWLin Wang
Lin Wang
XYXudong Yan
Xudong Yan
JZJiajia Zi
Jiajia Zi
YJYan Jiang
Yan Jiang
Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) is an immunologic disease, and pyroptosis, an inflammation-based cellular death, strictly modulates CRSwNP pathology, whereas the pyroptosis genes and mechanisms involved in CRSwNP remain unclear. Herein, we explored disease biomarkers and potential therapeutic targets for pyroptosis and immune regulation in CRSwNP using bioinformatics analysis and tissue-based verification. Methods: We retrieved the transcriptional profiles of the high-throughput dataset GSE136825 from the Gene Expression Omnibus database, as well as 170 pyroptosis-related gene expressions from GeneCards. Using R, we identified differentially expressed pyroptosis-related genes and examined the potential biological functions of the aforementioned genes using Gene Ontology, Kyoto Encyclopedia of the Genome pathway, immune infiltration, and protein-protein interaction (PPI) network analyses, thereby generating a list of hub genes. The hub genes were, in turn, verified using real-time quantitative polymerase chain reaction (qRT-PCR), immunohistochemistry (IHC), and Western blotting (WB). Ultimately, using the StarBase and miRTarBase databases, we estimated the targeting microRNAs and long chain non-coding RNAs. Results: We demonstrated that the identified pyroptosis-related genes primarily modulated bacterial defense activities, as well as inflammasome immune response and assembly. Moreover, they were intricately linked to neutrophil and macrophage infiltration. Furthermore, we validated the tissue contents of hub genes AIM2, NLPR6, and CASP5 and examined potential associations with clinical variables. We also developed a competitive endogenous RNA (ceRNA) modulatory axis to examine possible underlying molecular mechanisms. Conclusion: We found AIM2, CASP5, and NLRP6, three hub genes for pyroptosis in chronic rhinosinusitis with nasal polyps, by biological analysis, experimental validation, and clinical variable validation.